Cobitolimod, Index Pharmaceuticals' drug candidate for ulcerative colitis, has gained an orphan drug designation from the FDA as a treatment of children. The Toll-like receptor 9 agonist is in midstage trials for adults.
Drug for ulcerative colitis in children gets orphan status
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.